May be useful when evaluating for systemic sclerosis or connective tissue disease associated with overlapping features of systemic sclerosis and/or myositis.
Tue, Thu, Sat
New York DOH Approval Status
Serum separator tube.
Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Plasma. Contaminated, hemolyzed, or severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year
The presence of PM/Scl-100 IgG antibody along with a positive ANA IFA nucleolar pattern is associated with connective tissue diseases such as polymyositis (PM), dermatomyositis (DM), systemic sclerosis (SSc), and polymyositis/systemic sclerosis overlap syndrome. The clinical relevance of PM/Scl-100 IgG antibody with a negative ANA IFA nucleolar pattern is unknown. PM/Scl-100 is the main target epitope of the PM/Scl complex, although antibodies to other targets not detected by this assay may occur.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|2003041||PM/Scl 100 Antibody, IgG||81732-0|
- Antinuclear Antibodies
- Antinuclear Antibody
- Fluorescent Antinuclear Antibodies
- PM/Sci-100 IgG
- PM1 Antibody